Sanford Research Usd

1. Merck Sharp & Dohme Corporation $703,807 24 payments
2. Eli Lilly and Company $344,466 22 payments
3. Janssen Research & Development, LLC $299,147 74 payments
4. AstraZeneca Pharmaceuticals LP $152,442 27 payments
5. Biotronik Inc. $133,720 793 payments
6. Vertex Pharmaceuticals Incorporated $126,141 8 payments
7. AstraZeneca UK Limited $22,589 9 payments
8. Allergan Inc. $5,343 3 payments
9. Medical Device Business Services, Inc. $1,750 1 payment
10. Sanofi US Services Inc. $1,660 1 payment

1. A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC $277,534 2 payments
2. A Phase 1B Open-Label Phase 2 Randomized, Double-Blinded Study Evaluating Nab-Paclitaxel and Gemcitabine With Or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer $210,427 6 payments
3. A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions $197,151 39 payments
4. Phase IB study of Pembrolizumab in combination with chemoradiotherapy CRT for locally-advanced squamous cell carcinoma of the head and neck SCCHN $175,900 3 payments
5. A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer NSCLC KEYNOTE-799. $112,699 4 payments
6. A Phase 2 Study of Prexasertib in Platinum-Resistant Or Refractory Recurrent Ovarian Cancer $87,505 5 payments
7. A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy $75,510 1 payment
8. Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy $58,380 28 payments
9. QP ExCELs $57,633 307 payments
10. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $42,480 8 payments

1. Other $488 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.